We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
Read MoreHide Full Article
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 16.1% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ACET has moved about 1% on a year-to-date basis. In comparison, Medical companies have returned an average of -5.8%. This shows that Adicet Bio, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Biodesix, Inc. (BDSX - Free Report) . The stock is up 117.8% year-to-date.
Over the past three months, Biodesix, Inc.'s consensus EPS estimate for the current year has increased 17.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 430 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, this group has lost an average of 0.4% so far this year, meaning that ACET is performing better in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 62-stock industry is ranked #79. The industry has moved -11.2% so far this year.
Adicet Bio, Inc. and Biodesix, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Adicet Bio, Inc. (ACET - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Adicet Bio, Inc. is a member of our Medical group, which includes 884 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. Adicet Bio, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for ACET's full-year earnings has moved 16.1% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ACET has moved about 1% on a year-to-date basis. In comparison, Medical companies have returned an average of -5.8%. This shows that Adicet Bio, Inc. is outperforming its peers so far this year.
One other Medical stock that has outperformed the sector so far this year is Biodesix, Inc. (BDSX - Free Report) . The stock is up 117.8% year-to-date.
Over the past three months, Biodesix, Inc.'s consensus EPS estimate for the current year has increased 17.4%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Adicet Bio, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 430 individual stocks and currently sits at #107 in the Zacks Industry Rank. On average, this group has lost an average of 0.4% so far this year, meaning that ACET is performing better in terms of year-to-date returns.
Biodesix, Inc., however, belongs to the Medical Services industry. Currently, this 62-stock industry is ranked #79. The industry has moved -11.2% so far this year.
Adicet Bio, Inc. and Biodesix, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.